Sector
PharmaceuticalsOpen
₹126.53Prev. Close
₹124.05Turnover(Lac.)
₹10.01Day's High
₹126.53Day's Low
₹121.152 Week's High
₹133.552 Week's Low
₹30Book Value
₹-6.93Face Value
₹10Mkt Cap (₹ Cr.)
458.6P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 34.04 | 14.2 | 14.2 | 10.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -54.17 | -60.4 | -48.83 | -48.22 |
Net Worth | -20.13 | -46.2 | -34.63 | -38.02 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 13.71 | 20.5 | 12.86 | 8.15 |
yoy growth (%) | -33.11 | 59.34 | 57.82 | -34.37 |
Raw materials | -15.58 | -16.07 | -9.93 | -5.63 |
As % of sales | 113.6 | 78.4 | 77.17 | 69.1 |
Employee costs | -2.49 | -3.2 | -3.35 | -3.31 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -9.92 | -3.49 | -4.47 | -5.72 |
Depreciation | -0.99 | -1.01 | -0.94 | -0.9 |
Tax paid | 0.15 | 0.23 | -0.04 | -0.08 |
Working capital | -1 | 5.04 | -2.12 | 3.97 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -33.11 | 59.34 | 57.82 | -34.37 |
Op profit growth | 285.21 | -48.9 | -17.46 | 16.26 |
EBIT growth | 221.53 | -23.19 | -30.22 | 2.73 |
Net profit growth | 77.87 | -28.13 | -22.05 | 5.62 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.3 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,613.75 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,512.75 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.2 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,225.7 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sai Sudhakar Vankineni
Independent Director
Sangari Kondal Reddy
Company Sec. & Compli. Officer
Dolly Mandhan
Additional Director
Chandra Mouliswar Reddy Gangavaram
Additional Director
Balasubba Reddy Mamilla
Additional Director
Vedavathi Gangavaram
Additional Director
Sidda Reddy Kanuparthi
Additional Director
Sharvari Swapnil Shinde
Survey No 252/1 Aroor Village,
Sadasivapet Mandal,
Telangana - 502291
Tel: 91-08455-250080/250280
Website: http://www.oxygentapharma.com
Email: [email protected]; [email protected]; info@sso
12-10-167,
Bharath Nagar,
Hyderbad - 500018
Tel: 91-040-23818475/76/2
Website: www.vccilindia.com
Email: [email protected]
Summary
Oxygenta Pharmaceutical Limited (Formerly known S S Organics Ltd) was incorporated as Private Limited Company in year 1990 and converted into a Limited Company in 1993, with the objective of carrying ...
Read More
Reports by Oxygenta Pharmaceutical Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.